On May 6, 2022 Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), reported that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will present at two upcoming investor conferences in May (Press release, Ambrx, MAY 6, 2022, View Source [SID1234613801]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bank of America 2022 Healthcare Conference. Dr. Tian will participate in an analyst led fireside chat on Wednesday, May 11 at 12:00 PM Pacific Time / 3:00 PM Eastern Time.

H.C. Wainwright Global Investment Conference. Dr. Tian will conduct a pre-recorded presentation that will be available on-demand on Tuesday, May 24 at 4:00 AM Pacific Time / 7:00 AM Eastern Time.

Interested parties can access the live and pre-recorded webcasts for these conferences from the Investor Relations section of the company’s website at www.Ambrx.com. The webcast replays will be available after the conclusion of the respective presentations for approximately 90 days.